The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population Anahita Bassir Nia, MD‡; Claire L. Mann, BA; Sharron Spriggs, MA; Daniel R. DeFrancisco, MD; Steven Carbonaro, MD; Lyla Parvez, MA; Igor I. Galynker, MD, PhD; Charles A. Perkel, MD; and Yasmin L. Hurd, PhD Journal of Clinical Psychiatry, 2019, 80, (4), 18m12539 https://doi.org/10.4088/JCP.18m12539 Background : Current evidence suggests that women are more sensitive to the effects of cannabinoids. The aim of this study was to investigate the relevance of sex in the association of synthetic cannabinoid (SC) use with psychosis and agitation. Methods : A [...]
Lire la suitePsilocybin – Summary of knowledge and new perspectives Filip Tylš, Tomáš Páleníček, Jiří Horáček European Neuropsychopharmacology, 2014, 24, 342–356 Doi : 10.1016/j.euroneuro.2013.12.006 Abstract Psilocybin, a psychoactive alkaloid contained in hallucinogenic mushrooms, is nowadays given a lot of attention in the scientific community as a research tool for modeling psychosis as well as due to its potential therapeutic effects. However, it is also a very popular and frequently abused natural hallucinogen. This review summarizes all the past and recent knowledge on psilocybin. It briefly deals with its history, discusses the pharmacokinetics and pharmacodynamics, and compares its action in humans and animals. It attempts to describe the mechanism of psychedelic effects [...]
Lire la suiteHallucinogen persisting perception disorder after psilocybin consumption : a case study Marie-Laure Espiard, Laurent Lecardeur, Pascale Abadie, Isabelle Halbecq, Sonia Dolfuss European Psychiatry, 2005, 20, (5-6), 458-60 DOI: 10.1016/j.eurpsy.2005.04.008 Abstract The recurrence of flashbacks without acute or chronic hallucinogen consumption has been recognized in the DSM IV criteria as the hallucinogen persisting perception disorder (HPPD). Perceptual disturbances may last for 5 years or more and represent a real psychosocial distress. We reported here a case of a 18 year-old young man presenting HPPD after a mixed intoxication with psylocibin and cannabis. This report shows symptomatic recurrences persisting more than 8 months. Various differential diagnoses were [...]
Lire la suiteSurvey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]
Lire la suiteHarm potential of magic mushroom use : A review Jan van AMSTERDAM, Antoon OPPERTHUIZEN, Wim van den BRINK Regulatory Toxicology and Pharmacology, 2011, 59, 423-429. Doi : 10.1016/j.yrtph.2011.01.006 Abstract In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms. The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the [...]
Lire la suiteMaternal Marijuana Use, Adverse Pregnacy Outcomes and Neonatal Morbidity, Torri D. Metz et al., 2017
Maternal Marijuana Use, Adverse Pregnancy Outcomes and Neonatal Morbidity Torri D. Metz, Ms Amanda A. Allshouse, Carol J. Rowland Hogue, Robert L. Goldenberg, Donald J. Dudley, Michael W. Varner, Deborah L. Conway, George R. Saade, and Robert M. Silver American Journal of Obstetrics and Gynecology, 2017 October ; 217, (4), 478.e1–478.e8. doi :10.1016/j.ajog.2017.05.050 Abstract Background—The NICHD Stillbirth Collaborative Research Network (SCRN) previously demonstrated an association between stillbirth and maternal marijuana use as defined by the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC) in the umbilical cord homogenate. However, the relationship between marijuana use and perinatal complications in live births is uncertain. Objective—Our aim was to examine if [...]
Lire la suiteMedical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteLSD before Leary - Sidney Cohen' s Critique of 1950s Psychedelic Drug Research Steven J. Novak Isis, 1997, Vol. 88, No. 1, pp. 87-110. http://links.jstor.org/sici?sici=0021-1753%28199703%2988%3A1%3C87%3ALBLSCC%3E2.0.CO%3B2-W ABSTRACT In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychoto-mimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were [...]
Lire la suiteIbogaine : A review - Chapter 1 Kenneth R. Alper The Alkaloids. Chemistry and Biology, 2001, 56, 38 pp DOI: 10.1016/S0099-9598(01)56005-8 I. Introduction, Chemical Properties, and Historical Time Line ..................... A. Introduction................................................................................................... B. Chemical Structure and Properties .............................................................. C. Historical Time Line ..................................................................................... II. Mechanisms of Action .................................................................................. A. Neurotransmitter Activities........................................................................... B. Discrimination Studies.................................................................................. C. Effects on Neuropeptides............................................................................... D. Possible Effects on Neuroadaptations Related to Drug Sensitization or Tolerance ....................................................................................................... III. Evidence of Efficacy in Animal Models........................................................ A. Drug Self-Administration .............................................................................. B. Acute Opioid Withdrawal .............................................................................. C. Conditioned Place Preference........................................................................ D. Locomotor Activity........................................................................................ E. Dopamine Efflux............................................................................................. IV Evidence of Efficacy and Subjective Effects in Humans .............................. A. Evidence of Efficacy........................................................................................ B. Subjective Effects ........................................................................................... V. Pharmacokinetics ........................................................................................... A. Absorption....................................................................................................... B. Distribution .................................................................................................... C. Metabolism .................................................................................................... D. Excretion [...]
Lire la suitePsilocybin Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Fco. Miguel Ríos & Genís Oña - 2014 - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org Content _____________________________________ 1. What is Psilocybin? 2. Scientific papers about Psilocybin arranged chronologically (1959-2014) - A. Hofmann (1959). Chemical Aspects of Psilocybin, the Psychotropic Principle from the Mexican Fungus, Psilocybe Mexicana Heim - S. Malitz et al. (1960). Some Observations on Psilocybin, a New Hallucinogen, in Volunteer Subjects - L. E. [...]
Lire la suite